...
首页> 外文期刊>British journal of neurosurgery >Giant pituitary adenomas--an enigma revisited. Microsurgical treatment strategies and outcome in a series of 250 patients.
【24h】

Giant pituitary adenomas--an enigma revisited. Microsurgical treatment strategies and outcome in a series of 250 patients.

机译:巨大的垂体腺瘤-再访谜团。一系列250例患者的显微外科治疗策略和结果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Giant pituitary adenomas (> 4 cm) are a surgical challenge. We present our experiences in surgical management of these tumors in a series of 250 patients. METHODS: Two hundred and fifty patients with giant pituitary adenomas were managed surgically at our center over last 13 years. Majority (92%) of patients presented with visual deterioration. Non-functioning tumors were found in 136 patients (54.3%). Among functioning adenomas, 63 patients (25.4%) had prolactinomas and 45 patients (18%) had GH-secreting adenomas; while 3 patients each had LH and ACTH- secreting adenomas. The maximum tumor diameter varied from 4 to 10.5 cm, with mean diameter of 5.4 cm. The factors determining choice of operative approach and surgical outcomes in these tumors were analyzed. RESULTS: Overall, 273 surgical procedures were performed in 250 patients. Of these, 110 were transsphenoidal, while 163 were transcranial approaches. A single surgical procedure was performed in 227 patients (89.2%). 23 patients (9.2%) underwent re-exploration either because of postoperative apoplexy or residual tumor. Overall, near total (>90%) tumor excision could be achieved in 74%, with improved vision in 53% and good outcome in 75% patients. The mortality and morbidity were 4.4% and 14%, respectively. CONCLUSIONS: The main goal of surgical treatment of giant pituitary adenoma is maximum possible tumor extirpation with minimal side effects, which can be achieved by careful preoperative planning of operative approach, based on directions of tumor extensions and invasiveness. Maximal surgical removal of giant adenomas offers best chances to control tumor growth when followed with adjuvant medical and radiation therapies.
机译:背景:巨大的垂体腺瘤(> 4 cm)是一项手术挑战。我们介绍了在一系列250例患者中对这些肿瘤进行手术治疗的经验。方法:过去13年来,我们中心通过外科手术治疗了250例巨大的垂体腺瘤患者。绝大多数(92%)患者出现视力下降。在136例患者中发现了无功能的肿瘤(54.3%)。在功能性腺瘤中,泌乳素瘤患者63例(占25.4%),分泌GH的腺瘤患者45例(占18%)。 3例患者均患有LH和ACTH分泌腺瘤。最大肿瘤直径从4到10.5 cm不等,平均直径为5.4 cm。分析了决定这些肿瘤的手术方法选择和手术结果的因素。结果:总共对250例患者进行了273例手术。其中,110处是经蝶窦入路,而163处是经颅入路。 227名患者(89.2%)进行了一次手术。由于术后中风或残留肿瘤,对23例患者(9.2%)进行了再次探查。总体而言,在74%的患者中可达到近乎全部(> 90%)的肿瘤切除率,在53%的患者中可改善视力,在75%的患者中可获得良好的预后。死亡率和发病率分别为4.4%和14%。结论:巨大垂体腺瘤的外科手术治疗的主要目标是最大程度地切除肿瘤,并减少副作用,这可以通过根据肿瘤扩展和侵袭性的方向仔细进行术前术前计划来实现。辅以药物和放射疗法后,最大程度地手术切除巨大的腺瘤可提供最佳机会来控制肿瘤的生长。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号